Advancing Solutions to Combat Antimicrobial Resistance
At Ahmed AMR Lab, our research is dedicated to addressing the growing threat of antimicrobial resistance (AMR). We integrate microbiology and pharmacology to tackle this critical challenge through innovative approaches that aim to discover new treatments, develop protective vaccines, and deepen our understanding of host-pathogen interactions.
By bridging basic science and clinical application, we aim to develop comprehensive strategies to curb AMR, prevent infections, and improve treatment outcomes. Our research contributes to global health efforts by providing new tools and insights to manage resistant pathogens effectively.
Antimicrobial resistance research plays a pivotal role in advancing the One Health initiative, which emphasizes the interconnected health of humans, animals, and the environment. By uncovering how resistance develops and spreads across these domains, AMR research equips policymakers, healthcare providers, and agricultural stakeholders with evidence-based strategies to mitigate risks.
It fosters integrated surveillance systems, promotes responsible antibiotic use in medical and veterinary practices, and drives innovation in alternative therapies and preventive measures.
Ultimately, this research underscores the shared responsibility in combating AMR, ensuring sustainable health solutions that benefit all facets of life.
Purdue University’s leading researchers tackle complex challenges with real-world impact at the intersection of human, animal and plant health. Through academic programs, research, facility infrastructure and industry partnerships, Purdue is making giant leaps in improving health outcomes for all living things and driving economic growth regionally and globally.
Our work thrives on collaboration. We actively seek partnerships with researchers, industry experts, and academic institutions to drive innovation and bring our discoveries closer to real-world application. Contact Dr. Hassan to discuss opportunities at ahmed@purdue.edu.
Our research aims to enhance the pharmacodynamic and pharmacokinetic properties of drugs, improving their efficacy against resistant bacteria and fungi.
We evaluate the optimal routes of vaccine administration to maximize protection, with a focus on gastrointestinal pathogens like Clostridioides difficile and vancomycin-resistant Enterococcus.
These studies aim to uncover novel therapeutic targets and enhance infection management strategies by combining antibiotics with adjunctive treatments like anti-inflammatory drugs.
